Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04697693 · ClinicalTrials.gov registry record · Phase 4
Antidepressant Response in Older Adults With Comorbid PTSD and MDD
A Phase 4 study, sponsored by New York State Psychiatric Institute.
- Terminated
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
NCT04697693 is a Phase 4 study that was terminated before completion, run by New York State Psychiatric Institute. The registered enrollment target is 1 participants.
The verdict
NCT04697693, a Phase 4 study, was terminated before completion, sponsored by New York State Psychiatric Institute.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
Study Summary
In the Investigator's ongoing studies of Posttraumatic Stress Disorder (PTSD) in older adults, it has been found that older adults with PTSD frequently meet the criteria for comorbid Major Depressive Disorder (MDD). Moreover, relative to trauma-exposed healthy controls (TEHCs), elders with PTSD manifest executive function deficits, fatigability, and mobility and physical function deficits that are consistent with what the investigator has observed in depressed older adults. Yet, the investigator has found that very few older adults with combined PTSD/MDD have received appropriate antidepressant treatment for their condition. These findings give rise to the questions of (1) how effective is antidepressant treatment for depressive symptoms in the context of PTSD/MDD and (2) are cognitive and physical function deficits in PTSD/MDD patients reversible with effective antidepressant treatment?
Interventions
- DRUG Duloxetine
- DRUG Escitalopram
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2021-03-03 |
| Est. Completion | 2021-05-20 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04697693
The ClinicalTrials.gov registry entry for NCT04697693 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Duloxetine is the first listed.
NCT04697693 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04697693 about?
NCT04697693 is a clinical study titled "Antidepressant Response in Older Adults With Comorbid PTSD and MDD". In the Investigator's ongoing studies of Posttraumatic Stress Disorder (PTSD) in older adults, it has been found that older adults with PTSD frequently meet the criteria for comorbid Major Depressive Disorder (MDD). Moreover, relative to trauma-exposed healthy controls (TEHCs), elders with PTSD mani...
What is the current status of trial NCT04697693?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2021-03-03. Estimated completion is 2021-05-20.
What interventions are being tested in trial NCT04697693?
The interventions under investigation include: Duloxetine (DRUG), Escitalopram (DRUG).
Who is sponsoring clinical trial NCT04697693?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.